{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:17:57Z","timestamp":1793499477702,"version":"4.5.0"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder associated with insulin resistance and cardiovascular risk. The long-term association of ovarian morphology subtypes with long-term morbidity and mortality remains unclear.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether long-term morbidity and mortality differ among women with PCOS with or without polycystic ovarian morphology (PCOM).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This prospective cohort study was conducted from 1987 to 2005 with follow-up until 2024 (37 years) at a single academic referral center where women with PCOS consented for long-term health monitoring. Of 1089 initially enrolled women, 340 women with PCOS and sonographic data at baseline were included. Data were analyzed from January to April 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Ovarian morphology was defined by the presence (PCOM) or absence (non-PCOM) of 12 or more peripherally distributed 2- to 9-mm follicles.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n All-cause mortality and chronic morbidity, including diabetes and cardiovascular, neurologic, thyroid, respiratory, gastrointestinal, kidney, autoimmune, psychiatric, and cancer conditions were assessed. Demographics, hormone levels, and cardiovascular risk factors were collected at enrollment. Outcomes were assessed at follow-up in older age, with data analyzed using \u03c7\n 2<\/jats:sup>\n tests,\n t<\/jats:italic>\n tests, and multivariate logistic regression adjusted for confounders (baseline age, body mass index, fasting insulin, lipids, and follow-up duration).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 340 women with PCOS, 189 women had PCOM (mean [SD] age at enrollment, 28.03 [5.98] years) and 151 women did not (mean [SD] age at enrollment, 32.57 [9.21] years). Women with PCOM were younger at enrollment (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), with higher mean (SD) body mass index (27.20 [5.74] vs 25.31 [6.31];\n P<\/jats:italic>\n \u2009=\u2009.004), cholesterol ratios (70.64 [51.76] vs 48.36 [51.84];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), and levels of luteinizing hormone (7.28 [8.60] mIU\/mL vs 3.47 [4.39] mIU\/mL;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), androgens (eg, total testosterone: 90.78 [37.18] ng\/dL vs 52.74 [76.66] ng\/dL;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), fasting insulin (12.84 [9.83] \u03bcIU\/mL vs 8.85 [6.33] \u03bcIU\/mL;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), total cholesterol (167.57 [63.32] mg\/dL vs 147.1 [82.24] mg\/dL;\n P<\/jats:italic>\n \u2009=\u2009.01), and triglycerides (97.35 [72.57] mg\/dL vs 72.57 [61.06] mg\/dL;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Mean (SD) follow-up duration was shorter in women with PCOM (33.7 [2.3] years vs 35.1 [4.9] years;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Mortality rates were similar, although mean (SD) age at death was younger in women with PCOM (54.3 [11.5] years vs 70.8 [13.6] years;\n P<\/jats:italic>\n \u2009=\u2009.08). Non\u2013insulin-dependent diabetes was significantly more common in women with PCOM (45 women [23.8%] vs 14 women [9.3%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Hypertension was not statistically significantly different in women with PCOM. Multivariate analysis confirmed the association of PCOM with non\u2013insulin-dependent diabetes (aOR, 2.92; 95% CI, 1.06-2.82;\n P<\/jats:italic>\n \u2009=\u2009.02). No other significant differences in chronic diseases were observed.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this study, the PCOM pattern was associated with early metabolic abnormalities and increased risk of type 2 diabetes but not with increased mortality or other chronic diseases.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.40818","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T15:31:00Z","timestamp":1761924660000},"page":"e2540818","source":"Crossref","is-referenced-by-count":11,"title":["Polycystic Ovarian Morphology and Chronic Morbidity and Mortality in PCOS"],"prefix":"10.1001","volume":"8","author":[{"given":"Nir","family":"Kugelman","sequence":"first","affiliation":[{"name":"Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada"},{"name":"Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David V.","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pier","family":"Bastrash","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada"},{"name":"Medical School, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tehila","family":"Feinberg","sequence":"additional","affiliation":[{"name":"Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Miconiatis","sequence":"additional","affiliation":[{"name":"Medical School, McGill University, Montreal, Quebec, Canada"},{"name":"Department of Pathology, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordanna","family":"Rehany","sequence":"additional","affiliation":[{"name":"Department of Nursing, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seang Lin","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Dahan","sequence":"additional","affiliation":[{"name":"Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"issue":"1","key":"zoi251118r1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).","volume":"19","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","journal-title":"Hum Reprod"},{"issue":"4","key":"zoi251118r2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.5812\/ijem.4020","article-title":"Cardiovascular risk in women with PCOS.","volume":"10","author":"Scicchitano","year":"2012","journal-title":"Int J Endocrinol Metab"},{"issue":"4","key":"zoi251118r3","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1210\/jc.2004-1045","article-title":"Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.","volume":"90","author":"Apridonidze","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"zoi251118r4","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1590\/S0004-27302007000600012","article-title":"Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors.","volume":"51","author":"Marcondes","year":"2007","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"12","key":"zoi251118r5","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.","volume":"98","author":"Legro","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"zoi251118r6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1210\/er.2015-1104","article-title":"The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited.","volume":"37","author":"Rosenfield","year":"2016","journal-title":"Endocr Rev"},{"issue":"9","key":"zoi251118r7","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/humrep\/dey256","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.","volume":"33","author":"Teede","year":"2018","journal-title":"Hum Reprod"},{"issue":"2","key":"zoi251118r8","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/humrep\/dep399","article-title":"The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.","volume":"25","author":"March","year":"2010","journal-title":"Hum Reprod"},{"key":"zoi251118r9","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7624932","article-title":"Genetic variants associated with hyperandrogenemia in PCOS pathophysiology.","volume":"2018","author":"Dadachanji","year":"2018","journal-title":"Genet Res Int"},{"key":"zoi251118r10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43042-019-0031-4","article-title":"Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review.","volume":"20","author":"Ashraf","year":"2019","journal-title":"Egypt J Med Hum Genet"},{"issue":"3","key":"zoi251118r11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4274\/tjod.galenos.2022.63255","article-title":"Relationship between the follicular distribution pattern of polycystic ovaries and the degree of menstrual disturbance and serum sex steroid levels.","volume":"19","author":"Mills","year":"2022","journal-title":"Turk J Obstet Gynecol"},{"issue":"1","key":"zoi251118r12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.fertnstert.2011.09.024","article-title":"Consensus on women\u2019s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE\/ASRM-Sponsored 3rd PCOS Consensus Workshop Group.","volume":"97","author":"Fauser","year":"2012","journal-title":"Fertil Steril"},{"issue":"3","key":"zoi251118r13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.fertnstert.2014.12.094","article-title":"Ultrasound features of polycystic ovaries relate to degree of reproductive and metabolic disturbance in polycystic ovary syndrome.","volume":"103","author":"Christ","year":"2015","journal-title":"Fertil Steril"},{"issue":"12","key":"zoi251118r14","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1210\/jc.2011-1677","article-title":"Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study.","volume":"96","author":"Schmidt","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"zoi251118r15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1210\/jc.2005-1329","article-title":"Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.","volume":"91","author":"Ehrmann","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"zoi251118r16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1046\/j.1365-2265.2000.01000.x","article-title":"Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study.","volume":"52","author":"Wild","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"zoi251118r18","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.tem.2023.08.005","article-title":"Questioning PCOS phenotypes for reclassification and tailored therapy.","volume":"34","author":"Myers","year":"2023","journal-title":"Trends Endocrinol Metab"},{"key":"zoi251118r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.endmts.2024.100159","article-title":"When one size does not fit all: reconsidering PCOS etiology, diagnosis, clinical subgroups, and subgroup-specific treatments.","volume":"14","author":"Unfer","year":"2024","journal-title":"Endocr Metab Sci"},{"issue":"4","key":"zoi251118r20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/AOG.0000000000005702","article-title":"Correlation of polycystic ovarian syndrome phenotypes with pregnancy and neonatal outcomes.","volume":"144","author":"Chan","year":"2024","journal-title":"Obstet Gynecol"},{"issue":"5","key":"zoi251118r21","doi-asserted-by":"publisher","first-page":"493.e1","DOI":"10.1016\/j.ajog.2017.01.003","article-title":"Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype.","volume":"216","author":"Engmann","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"9548","key":"zoi251118r22","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0140-6736(06)69701-8","article-title":"Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.","volume":"368","author":"Lindstr\u00f6m","year":"2006","journal-title":"Lancet"},{"issue":"5","key":"zoi251118r23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037887","article-title":"Adverse metabolic response to regular exercise: is it a rare or common occurrence?","volume":"7","author":"Bouchard","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"zoi251118r24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"zoi251118r17","unstructured":"National Institutes of Health Office of Disease Prevention. Evidence-based methodology workshop on polycystic ovary syndrome (PCOS). Eunice Kennedy Shriver National Institute of Child Health and Human Development. Accessed August 5, 2025. https:\/\/www.nichd.nih.gov\/newsroom\/resources\/spotlight\/112112-pcos"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2840789\/kugelman_2025_oi_251118_1761324839.97292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T15:31:01Z","timestamp":1761924661000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2840789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.40818","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]}}}